The effect of kallidinogenase for the retina thickness and visual acuity etc.after intravitreal bevacizumab for diabetic macula edema.

The effect of kallidinogenase for the retina thickness and visual acuity etc.after intravitreal bevacizumab for diabetic macula edema. - The effect of kallidinogenase for diabetic macula edema after intravitreal bevacizumab.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013174

Enrollment

Registered

2014-02-17

Start date

2014-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic macula edema

Interventions

Kallidinogenase(+)oral Kallidinogenase(-)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients underwent intravitreal bevacizumab for diabetic macula edema,who met the all inclusion criteria. (a)Older than 20tears of age at the time of the acquisition agreement. (b)Allowed to go to the Tsukazaki Hospital regularly for one year. (c)Obtained consentin written foem of the study participants.

Exclusion criteria

Exclusion criteria: (a)Sever side effects by the past kallidinogenase preparations. (b)Treated by kallidinogenase within one month of preparation before the start of this drug. (c)HbA1c 10%. (d)Treated with steroids drugs or laser photocoagulation for diabetic macula edema within four months (e)Pregnant and lactating woman or woman who may become pregnant. (f)Any others judged by the doctor in charge to be ineligible for subjects in the study.

Design outcomes

Primary

Measure	Time frame
Foveal retinal thickness,visual acuity	—

Secondary

Measure	Time frame
Recurrence of the edema,number of the exaples of aan ophthalmic treatment addition,number of the times of an addition,and period to an addition,the safety assessment(rate of adverse events)	—

Countries

Japan

Contacts

Public ContactZaigen Ohara

Tsukazaki hospital Ophthalmology

z.ohhara@tsukazaki-eye.net079-272-8555

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026